Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab with or without Gemcitabine and Docetaxel in Advanced Sarcoma
NCT04577014Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2020
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab in soft tissue sarcoma (STS), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2020; status: recruiting.
02
Drugs
retifanlimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04577014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577014.